proteomic-based diagnostics

The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.

Founded last year, the company plans to develop mass spec-based tests to protein isoforms using a workflow that eliminates both LC and protein digestion.

Genome Canada and its partners recently funded two new initiatives with C$255 that will back precision medicine, genomics, and technology development.

The company is developing an epilepsy test based on inflammatory proteins in patient blood that is intended for ruling out patients with seizure-like symptoms.

The company presented new data at a meeting last week showing that Vectra DA predicted whether patients would do better on one or the other of two possible second-line therapies.

NEW YORK (GenomeWeb) – Biocartis announced today that it has raised €64.5 million ($84 million) in a round of private financing.

NEW YORK (GenomeWeb) – Newomics said today that it has received from the National Institutes of Health two Small Business Innovation Research Phase I grants totaling $908,000.

NEW YORK (GenomeWeb) – Integrated Diagnostics said this week that it has obtained $47.25 million in funding, $30.25 million from the closing of its Series B round and $17 million in non-dilutive debt financing from Life Sciences Alternative Funding.

NEW YORK (GenomeWeb News) – Biodesix today said that it has closed an $8.3 million Series E round of private financing.

The story has been updated to include comments from Vermillion's conference call on Thursday.

Pages

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.